87321-06-0

Basic information

• Product Name: 8-[(5-aminopentan-2-yl)amino]-6-hydroxyquinolin-5(1H)-one
• CAS NO: 87321-06-0
• Molecular Formula: C₁₄H₁₉N₃O₂
• Molecular Weight: 261.3196
• Mol File: 87321-06-0.mol

Chemical Properties

• Boiling Point: 461.7°C at 760 mmHg
• Flash Point: 233°C
• Density: 1.25g/cm³
• Vapor Pressure: 1.83E-10mmHg at 25°C
• Refractive Index: 1.626
• CAS DataBase Reference: 8-[(5-aminopentan-2-yl)amino]-6-hydroxyquinolin-5(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 8-[(5-aminopentan-2-yl)amino]-6-hydroxyquinolin-5(1H)-one(87321-06-0)
• EPA Substance Registry System: 8-[(5-aminopentan-2-yl)amino]-6-hydroxyquinolin-5(1H)-one(87321-06-0)

Safety Data

• Hazardous Substances Data: 87321-06-0(Hazardous Substances Data)

Upstream product

• 59353-62-7 4-bromo-1-phthalimidopentane 
• 5333-02-8 5,6-dimethoxy-8-nitroquinoline 
• 6938-02-9 8-amino-5,6-dimethoxyquinoline 
• 47136-26-5 5,6-dimethoxy-8-<(4-amino-1-methylbutyl)amino>quinoline 
• 626-87-9 1,4-dibromopentane 

Relevant articles and documents

Primaquine-Induced Hemolytic Anemia: Susceptibility of Normal versus Glutathione-Depleted Rat Erythrocytes to 5-Hydroxyprimaquine

Primaquine is an important antimalarial agent because of its activity against exoerythrocytic forms of Plasmodium spp. Methemoglobinemia and hemolytic anemia, however, are dose-limiting side effects of primaquine therapy. These hemotoxic effects are believed to be mediated by metabolites, although the identity of the toxic specie(s) and the mechanism underlying hemotoxicity have remained unclear. Previous studies showed that an N-hydroxylated metabolite of primaquine, 6-methoxy-8-hydroxylaminoquinoline, was capable of mediating primaquine-induced hemotoxicity. The present studies were undertaken to investigate the hemolytic potential of 5-hydroxyprimaquine (5-HPQ), a phenolic metabolite that has been detected in experimental animals. 5-HPQ was synthesized, isolated by flash chromatography, and characterized by NMR spectroscopy and mass spectrometry. In vitro exposure of 51Cr-labeled erythrocytes to 5-HPQ induced a concentration-dependent decrease in erythrocyte survival (TC50 of ca. 40 μM) when the exposed cells were returned to the circulation of isologous rats. 5-HPQ also induced methemoglobin formation and depletion of glutathione (GSH) when incubated with suspensions of rat erythrocytes. Furthermore, when red cell GSH was depleted (>95%) by titration with diethyl maleate to mimic GSH instability in human glucose-6-phosphate dehydrogenase deficiency, a 5-fold enhancement of hemolytic activity was observed. These data indicate that 5-HPQ also has the requisite properties to contribute to the hemotoxicity of primaquine. The relative contribution of N-hydroxy versus phenolic metabolites to the overall hemotoxicity of primaquine remains to be assessed.

Antimalarial activity of primaquine operates via a two-step biochemical relay

Primaquine (PQ) is an essential antimalarial drug but despite being developed over 70 years ago, its mode of action is unclear. Here, we demonstrate that hydroxylated-PQ metabolites (OH-PQm) are responsible for efficacy against liver and sexual transmission stages of Plasmodium falciparum. The antimalarial activity of PQ against liver stages depends on host CYP2D6 status, whilst OH-PQm display direct, CYP2D6-independent, activity. PQ requires hepatic metabolism to exert activity against gametocyte stages. OH-PQm exert modest antimalarial efficacy against parasite gametocytes; however, potency is enhanced ca.1000 fold in the presence of cytochrome P450 NADPH:oxidoreductase (CPR) from the liver and bone marrow. Enhancement of OH-PQm efficacy is due to the direct reduction of quinoneimine metabolites by CPR with the concomitant and excessive generation of H2O2, leading to parasite killing. This detailed understanding of the mechanism paves the way to rationally re-designed 8-aminoquinolines with improved pharmacological profiles.